The use of serotonergic uptake inhibitors in the treatment of premature ejaculation

Kaplan, Peter M.

doi:10.1080/00926239408404382

Cited by 29 publications

(13 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Clinically, fluoxetine (a selective serotonin re‐uptake inhibitor) has been used to treat premature ejaculation [ 12–14]. While our previous study showed that fluoxetine was only 20‐fold more potent than prazosin in inhibiting rat seminal vesicle contraction [ 6], the present study showed that phenoxybenzamine and WB‐4101 were 665‐ and 103‐fold more potent, respectively.…”

Section: Discussionmentioning

confidence: 54%

An in vivo evaluation of the therapeutic potential of sympatholytic agents on premature ejaculation

1999

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 54%

An in vivo evaluation of the therapeutic potential of sympatholytic agents on premature ejaculation

1999

View full text Add to dashboard Cite

show abstract

“…However, their main effect is prolonged erection. Therefore, they have been used in the treatment of premature ejaculation in benefit from a side effect [1,10].…”

Section: Discussionmentioning

confidence: 99%

Terazosin in the Treatment of Premature Ejaculation: A Short-term Follow-up

et al. 2005

View full text Add to dashboard Cite

show abstract

“…Many papers have reported the successful treatment of PE with SSRIs (Kaplan, 1994; Mendels et al ., 1995; Swartz & Eatein, 1997; Mcmahon, 1998; Kim & Paick, 1999). Consistent with these studies, our study has shown that sertraline was effective for patients with primary PE ( p < 0.01).…”

Section: Discussionmentioning

confidence: 99%

Management of premature ejaculation – a comparison of treatment outcome in patients with and without erectile dysfunction

Chia

2002

Int J of Andrology

View full text Add to dashboard Cite

This study evaluated the problem of premature ejaculation (PE) in patients treated for erectile dysfunction. The aim was to compare the efficacy of selective serotonin reuptake inhibitors (SSRIs) in the management of primary PE and PE associated with sildenefil treatment. Eighty-seven patients with PE seen over a period of 17 months were recruited into this prospective study. They were categorized into two groups: primary PE (GPI) and PE in sildenefil-treated patients (GPII). All patients recruited into GPII had erectile dysfunction (ED) that was successfully treated with sildenefil citrate for at least a year. Both groups of patients were given sertraline 50 mg 4 h before expected time of sex. The minimum follow-up was 6 months. The ejaculation latency before and after treatment of the two groups were compared. The sexual satisfaction scores of the patients in the two groups were also sought and analysed. Twenty-eight percent of patients with ED who were successfully treated with sildenefil developed PE. Subjects in group GPI were younger and have less comorbid factors than those in group GPII. There was no significant difference in the mean ejaculation latency for both groups (46 vs. 34.6 sec for GPI and GPII, respectively). However, there was highly significant difference in the ejaculation latency between the two groups after treatment with sertraline for 6 months (247.2 vs. 111.6 sec for GPI and GPII, respectively). There was also significant difference in the sexual satisfaction score for group GPI post-treatment, but not for GPII. No significant side-effect of sertraline was reported from patients in both groups. Successful treatment of ED could not assure sexual satisfaction. At least a quarter of sildenefil treated ED patients might develop PE which would continue to frustrate these patients sexually. While selective serotonin re-uptake inhibitors (SSRIs) was effective in the management of primary PE, they were not as effective in patients with sildenefil corrected ED.

show abstract

The use of serotonergic uptake inhibitors in the treatment of premature ejaculation

Cited by 29 publications

References 1 publication

An in vivo evaluation of the therapeutic potential of sympatholytic agents on premature ejaculation

An in vivo evaluation of the therapeutic potential of sympatholytic agents on premature ejaculation

Terazosin in the Treatment of Premature Ejaculation: A Short-term Follow-up

Management of premature ejaculation – a comparison of treatment outcome in patients with and without erectile dysfunction

Contact Info

Product

Resources

About